In Brief: Cardiac Pathways Corp.
This article was originally published in The Gray Sheet
Cardiac Pathways Corp.: Receives investigational device exemption from FDA for its Arrhythmia Mapping System, a cardiac ablation system that utilizes a 64-electrode mapping "basket" catheter to "diagnose and treat patients with complex tachyarrhythmias." The Sunnyvale, California-based company says it will begin a multicentered feasibility study of the system within two weeks at Brigham & Women's Hospital in Boston and St. Mary's Hospital in Rochester, Minnesota. The study will make privately held Cardiac Pathways "the first company to begin clinical trials of an integrated mapping system in the left ventricle," according to the firm...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.